In 2010, 18,600 adults and children were diagnosed with acute leukemias (ALL and AML) with 10,400 expected deaths (55%). Among acute leukemias, ALL and AML subtypes with an oncogenic tyrosine kinase have a particularly high frequency of relapse and overall poor outcome. For instance, median disease-free survival (DFS) for standard AML is 20 months compared to 4.6 months for patients with FLT3ITD AML. Likewise, DFS for standard risk ALL is at 23.8 months compared to 8.7 months for patients with Ph+ ALL carrying the BCR-ABL1 tyrosine kinase. While initial TKI therapy for patients with FLT3ITD AML and Ph+ ALL is initially successful, TKI fail to eradicate leukemia-initiating cells42 and the leukemias invariably relapses. Therefore, TKD-leukemias represent a frequent unsolved clinical problem. By contrast, the advent of potent TKI has transformed CML into a long-term condition. With 4,870 patients newly diagnosed in 2010, currently 24,800 patients live with CML in the US with a 5-year overall survival of >95%. However, also in CML, TKI fail to eradicate LIC, thus TKI-treatment for CML patients is typically life-long since measurable amounts of LIC persist in the bone marrow and CML re-emerges once TKI-treatment ceases. Since recent work has implicated leukemia initiating cells (LIC) in both initial drug-resistance and relapse of the disease, current therapy approaches need to focus on LIC eradication. Acute and chronic myeloid leukemias develop hierarchically from a phenotypically distinct stem cell population. However, recent work suggests that no hierarchically distinct stem cell population exists in B cell lineage ALL7. In the absence of a stem cell hierarchy, we hypothesize that B cell linage ALL have the ability to temporarily acquire stem cell capabilities, i.e. the ability to initiate leukema in xenograft transplant recipients. We will thus test the hypothesis that TKD-leukemia cells can switch between 'Progenitor-like proliferation'and 'Stem cell-like quiescence'. We are proposing four Aims to (1) validate BCL6 as therapeutic target in TKD-leukemia, (2) define mechanistic elements of BCL6-dependent drug-resistance, (3) validate and prioritize three different approaches of pharmacological inhibition of BCL6 and (4) develop a Phase I clinical trial for BCL6 inhibition in adults with relapse TKD-leukemia.

Public Health Relevance

BCL6 is a master regulator that controls the expression of many different important genes. BCL6 was not previously known to be involved in leukemia. In preliminary studies for this proposal, we have discovered aberrant expression of BCL6 as a central component of a fundamentally novel pathway of drug-resistance in a wide array of human leukemias, most of which are still difficult to treat. In these leukemias, drug-treatment results in aberrant production of BCL6 by the leukemia cells, which allows leukemia cells to become resistant against chemotherapy. Recently, a compound has been developed that can attach to BCL6 and block its ability to confer resistance. We found that this BCL6 inhibitor has strong cooperative activity when combined with conventional chemotherapy. This opens up a powerful new therapeutic strategy for leukemia cell eradication through targeted inhibition of BCL6. Our proposal will elucidate the mechanism of BCL6-mediated drug- resistance and develop ways to use this information in novel anti-leukemia therapeutics.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
5R01CA169458-02
Application #
8662212
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Merritt, William D
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Pathology
Type
Schools of Medicine
DUNS #
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Swaminathan, Srividya; Duy, Cihangir; Muschen, Markus (2014) BACH2-BCL6 balance regulates selection at the pre-B cell receptor checkpoint. Trends Immunol 35:131-7
Buchner, Maike; Müschen, Markus (2014) Targeting the B-cell receptor signaling pathway in B lymphoid malignancies. Curr Opin Hematol 21:341-9
Papaemmanuil, Elli; Rapado, Inmaculada; Li, Yilong et al. (2014) RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet 46:116-25
Pan, Rongqing; Hogdal, Leah J; Benito, Juliana M et al. (2014) Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 4:362-75
Gang, E J; Hsieh, Y-T; Pham, J et al. (2014) Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene 33:2169-78
Mangum, D S; Downie, J; Mason, C C et al. (2014) VPREB1 deletions occur independent of lambda light chain rearrangement in childhood acute lymphoblastic leukemia. Leukemia 28:216-20
Tsai, Chiou-Tsun; Yang, Pei-Ming; Chern, Ting-Rong et al. (2014) AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine. Oncotarget 5:211-23
Kharabi Masouleh, Behzad; Geng, Huimin; Hurtz, Christian et al. (2014) Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 111:E2219-28
Ramezani-Rad, Parham; Geng, Huimin; Hurtz, Christian et al. (2013) SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. Blood 121:148-55